Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1999-5-27
pubmed:abstractText
The new rifamycin derivatives KRM-1657 and KRM-1648 were evaluated for their in vitro antimicrobial activities against 44 strains of Helicobacter pylori. Although the drugs were not very active against other gram-negative bacteria, the MICs at which 90% of isolates are inhibited for these drugs were lower (0.002 and 0.008 microgram/ml, respectively) than those of amoxicillin and rifampin for H. pylori. Time-kill studies revealed that the bactericidal activities of these agents were due to cell lysis. The results presented here indicate that these new rifamycin derivatives may be useful for the eradication of H. pylori infections.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-1520782, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-1590683, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-1891020, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-1891021, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-1971318, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-2039206, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-2642447, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-3050121, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-7486933, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-7492091, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-7628989, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-7695331, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-8067748, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-8270008, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-8448815, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-8489232, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-8592994, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-8651150, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-8675345, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-8722530, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-8830678, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-9252185, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-9274464, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-9284136, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-9398908, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-9420032, http://linkedlifedata.com/resource/pubmed/commentcorrection/10223916-9420062
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
43
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1072-6
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657.
pubmed:affiliation
Department of Microbiology, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't